Of chloroquine and COVID-19

Antiviral Res. 2020 May;177:104762. doi: 10.1016/j.antiviral.2020.104762. Epub 2020 Mar 5.

Abstract

Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community should consider this information in light of previous experiments with chloroquine in the field of antiviral research.

Keywords: 2019-nCoV; Antiviral; COVID-19; Chloroquine; SARS-CoV-2.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / adverse effects
  • Antiviral Agents / pharmacology
  • Antiviral Agents / standards
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus / drug effects
  • China
  • Chloroquine / adverse effects
  • Chloroquine / pharmacology
  • Chloroquine / standards
  • Chloroquine / therapeutic use*
  • Clinical Trials as Topic / standards
  • Coronavirus Infections / drug therapy*
  • Humans
  • Hydroxychloroquine / adverse effects
  • Hydroxychloroquine / pharmacology
  • Hydroxychloroquine / standards
  • Hydroxychloroquine / therapeutic use
  • Pandemics
  • Pneumonia, Viral / drug therapy*

Substances

  • Antiviral Agents
  • Hydroxychloroquine
  • Chloroquine

Supplementary concepts

  • COVID-19
  • severe acute respiratory syndrome coronavirus 2